Recently, 36Kr learned that Wuhan Landing Intelligent Medicine Co., Ltd. (hereinafter referred to as "Landing Shares"), a medical artificial intelligence company, has completed a 320 million yuan D round of financing led by Ali Health, this round of financing is led by Ali Health, and Ether Investment participates in the follow-up investment.
Landing is a long-established medical artificial intelligence enterprise founded by Dr. Sun Xiaorong. Xiaorong Sun has served at the Memorial Sloan Kettering Cancer Research Center in New York, usa, a researcher at the BC Cancer Institute in Canada, and a professor at Tongji Medical College in Wuhan. After many years of research on tumor pathology images abroad, Sun Xiaorong discovered the possibility of artificial intelligence being applied to the pathology field, and then returned to China to start a business. Pang Baochuan, chief technology officer of the company, is the deputy director of the Landing Artificial Intelligence Cytopathological Diagnosis Research Center of Wuhan University, a member of the Pathology Committee of the China Medical Equipment Artificial Intelligence Alliance, and the co-founder Wang Jian has also engaged in related research in many universities such as Rockefeller University in the United States, and the team has rich industry experience.
Pathological examination is the gold standard for tumor diagnosis, and the domestic pathology market size is about 50 billion yuan, of which cytopathology accounts for 75%. However, there is an extreme shortage of pathologists in China, there is 1 pathologist among 11,000 people in the United States, and 136,000 people in China have 1 pathologist, and the density of pathologists in China is less than 10% of that of the United States; in addition, the distribution of domestic pathologists is very uneven, most of them are in the top three hospitals, and the number of registered practicing pathologists in domestic first-level hospitals is less than 1% of China's overall pathologists. Therefore, the state encourages pathologists to practice at multiple points and uses AI empowerment to improve the efficiency and accuracy of pathological diagnosis.
Based on the actual clinical needs in the field of pathology, what Landing co., Ltd. does is to use artificial intelligence technology to do the early diagnosis of cancer cells, and the products and services cover sample production scanning, AI cloud diagnosis to report review and whole process quality monitoring. More specifically, Landing's products and services are divided into three parts: artificial intelligence diagnostic services, including full digital management, process tracking, intelligent diagnosis, digital quality control, remote diagnosis, report review and transmission; intelligent diagnostic terminal auxiliary equipment, including blood cell image analyzer, digital pathology analyzer, portable microscopic image scanner; supporting consumables, including staining solution, fixation solution, preservation solution, disposable swab, bar code list, application form, etc. It is worth mentioning that the samples uploaded to the AI pathology cloud platform will be sent back to independent medical laboratories for data labeling, and the company has accumulated tens of millions of cases of high-quality data.
At present, the company's cytopathology artificial intelligence cloud diagnosis technology has completed the whole chain construction and commercialization verification of single-disease cervical cancer screening, and the main source of the company's commercialization income is the government's large-scale cervical cancer screening project.
Landing co., Ltd. has 12 subsidiaries, has established 5 large artificial intelligence laboratories and 67 small and medium-sized artificial intelligence laboratories in China, and the company has completed 3 million AI cloud diagnostic screenings from all over the country, and its products have been used by more than 600 general hospitals. In addition, it provides artificial intelligence diagnosis services through the cloud platform, and has formed a stable cooperative relationship with thousands of hospitals and tens of thousands of streets and township grass-roots material collection sites, and the business network covers the whole country. At present, nearly 10 million women in China have provided high-quality and low-cost cervical cancer screening services.
For future development, Sun Xiaorong said that the company will promote artificial intelligence cytology cervical cancer screening technology to the remote early diagnosis and rapid diagnosis of other high-incidence tumors in the clinic, such as thyroid, breast, gastrointestinal cancer and other remote early diagnosis and rapid diagnosis while contributing to the target of full coverage screening for 300 million women. In addition, Landing's artificial intelligence cloud diagnostic business will also cooperate with Alibaba Health Platform to expand the To C market.
In recent years, the AI medical imaging industry is a hot spot in the market, and many companies have obtained large amounts of financing, of which 4 companies, including Keya Medical, have submitted listing prospectuses to the Hong Kong Stock Exchange. In the early entrepreneurial process, each company started from a core product, but at present, each company has moved from a single part to a multi-site, multi-disease, and enriched the product line layout.
![To see how strong the AI is, someone took it to play a "script kill"[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)